Corporate Update: Genmab A/S Announces Positive Outcomes from Phase 3 EPCORE DLBCL‑4 Trial
Genmab A/S (BSE: GEN) announced that the Phase 3 EPCORE DLBCL‑4 study, which assessed the efficacy and safety of a bispecific antibody, epcoritamab, in combination with lenalidomide, met its primary endpoint of improving progression‑free survival (PFS) in patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL). The topline data were presented to the scientific community in a recent press release and will be further discussed with regulatory authorities and presented at forthcoming medical conferences.
Study Design and Population
- Population: Adults with relapsed or refractory DLBCL who had received at least two prior lines of therapy, including a rituximab‑containing regimen.
- Randomization: 1:1 allocation to either the combination arm (epcoritamab + lenalidomide) or standard-of-care investigator‑chosen therapy (ITC).
- Endpoints: The primary endpoint was investigator‑assessed PFS. Secondary endpoints included overall survival (OS), overall response rate (ORR), duration of response (DOR), and safety.
- Censoring Rules: Two censoring strategies were applied: (1) censoring at the date of subsequent anti‑lymphoma therapy, and (2) censoring at the date of any progression or death. The benefit estimates varied modestly between the two approaches.
Efficacy Outcomes
| Metric | Combination (epcoritamab + lenalidomide) | Standard‑of‑Care (ITC) | Hazard Ratio (HR) | 95% CI | P‑value |
|---|---|---|---|---|---|
| Progression‑free survival (US) | 60 % risk reduction | 0 % | 0.40 | 0.30–0.55 | <0.001 |
| Progression‑free survival (outside US) | 56 % risk reduction | 0 % | 0.44 | 0.33–0.58 | <0.001 |
| Overall response rate | 54 % | 22 % | – | – | – |
| Duration of response | 12.3 mo | 5.7 mo | – | – | – |
The hazard ratios reported represent a relative reduction in the risk of disease progression or death, with a consistent benefit observed both in the United States and internationally. The magnitude of the benefit is clinically meaningful and aligns with outcomes seen in other bispecific antibody studies for B‑cell malignancies.
Safety Profile
The combination’s safety profile was largely consistent with the known adverse event (AE) spectra of epcoritamab and lenalidomide individually:
- Infusion‑related reactions (IRRs): 32 % of patients experienced grade 1–2 IRRs, primarily mild and managed with pre‑medication and dose adjustments. No grade 3–4 IRRs were reported.
- Cytokine release syndrome (CRS): 5 % of patients had CRS events, all grade 1–2, reversible with standard supportive care.
- Infections: 18 % of patients experienced grade 3–4 infections, predominantly neutropenic fever, requiring antimicrobial therapy.
- Hematologic toxicities: Grade 3–4 neutropenia in 21 % of patients; thrombocytopenia in 12 %.
- Other AEs: Hypersensitivity reactions (3 %), alopecia (8 %), and fatigue (24 %) were reported.
No new safety signals were identified, and the incidence of serious adverse events (SAEs) remained comparable between the combination arm and ITC.
Regulatory Implications
Genmab, in partnership with AbbVie, will engage with regulatory authorities—including the FDA, EMA, and other global agencies—to discuss the data and potential for accelerated or conditional approvals. The robust PFS benefit and manageable safety profile support a compelling case for expanding epcoritamab indications, potentially addressing unmet needs in later‑line DLBCL treatment.
Future Directions
The company highlighted ongoing clinical development programs:
- Fixed‑duration epcoritamab with lenalidomide in newly diagnosed and relapsed DLBCL to evaluate whether a short course can maintain durable responses while reducing cumulative toxicity.
- Combination with other agents (e.g., checkpoint inhibitors, CAR‑T cell products) to explore synergistic mechanisms and broaden therapeutic options.
- Expansion into other B‑cell lymphomas (e.g., follicular lymphoma, mantle cell lymphoma) through dedicated Phase 3 trials.
Practical Implications for Patient Care
- Efficacy: The significant improvement in PFS may translate into longer disease control and potentially better long‑term survival, especially for patients with limited treatment options after multiple lines of therapy.
- Safety: The manageable AE profile, particularly the low incidence of severe CRS and IRRs, suggests that the combination can be administered in outpatient infusion centers with standard pre‑medication protocols.
- Treatment Sequencing: Positive data reinforce the rationale for incorporating epcoritamab early in the treatment algorithm for relapsed DLBCL, possibly shifting the standard of care paradigm toward bispecific antibody‑based regimens.
- Health‑system Impact: While the upfront costs of biologic therapies remain high, the potential for reduced hospitalization due to fewer severe AEs and the possibility of fixed‑duration treatment could mitigate overall resource utilization.
In summary, Genmab’s Phase 3 EPCORE DLBCL‑4 results demonstrate a statistically and clinically meaningful improvement in progression‑free survival for patients with relapsed or refractory DLBCL, with a safety profile consistent with the individual agents. These findings bolster the evidence base for epcoritamab‑based therapies across multiple lines of treatment for B‑cell lymphomas and underscore the company’s commitment to advancing the antibody in additional clinical settings.
